Velcade Wins FDA Clearance In First-Line MM
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency hits PDUFA date with “quite broad” new label, exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment
Spurred by backing of physician opinion leaders, sales grow quickly ahead of first-line filing, which is expected in the second half of 2010.
Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment
Spurred by backing of physician opinion leaders, sales grow quickly ahead of first-line filing, which is expected in the second half of 2010.
Celgene’s Revlimid Gains Blockbuster Status; Vidaza Poised To Gobble MDS Market Share
NICE posts positive recommendation for Vidaza payment in England, Wales.